Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Helmholtz Zentrum München | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
In this mono-center pilot trial, polytrauma patients admitted to intensive care will be included. Investigators are going to take blood and muscle samples at respecified time points to do metabolic, histological and molecular testing.
Aim of the study is to investigate (1) changes of the blood metabolome in patients with ICUAW (intensive care unit acquired weakness) and (2) identify metabolic components who are responsible for ICUAW or can be used as marker for ICUAW.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Intensive Care Patients | Polytrauma patients who have been admitted to intensive care |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Metabolomics | Blood Metabolome will be isolated from blood samples. All samples will be screened for changes in the blood metabolome during muscle wasting (i.e. Intensive Care Unit Acquired Weakness) using mass spectrometry | a median of 14 days |
| Measure | Description | Time Frame |
|---|---|---|
| Muscle histology | Immunohistochemistry will be done in muscle samples. All samples will be screened for changes in the muscular structure and correlation with blood metabolome changes. | a median of 14 days |
| Phosphoproteomics |
| Measure | Description | Time Frame |
|---|---|---|
| Identify possible predictors of muscle wasting in the blood metabolome at ICU admission | Identify metabolites or combinations of metabolites whose high or low concentration(s) at ICU admission associate(s) with the amount of muscle loss. These metabolites are candidate biomarkers that could be used to identify individuals at risk of large muscle wasting and may give further insights into the mechanisms of muscle wasting. |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
polytrauma patients who are admitted to intensive care
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Stefan J Schaller, MD, MHBA | Technical University of Munich | Principal Investigator |
| Hennig Wackerhage, PhD | Technical University of Munich | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Klinikum rechts der Isar, School of Medicine, Technical University of Munich | Munich | Bavaria | 81675 | Germany |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D016638 | Critical Illness |
| D011115 | Polyneuropathies |
| D009135 | Muscular Diseases |
| D018908 | Muscle Weakness |
| ID | Term |
|---|---|
| D020969 | Disease Attributes |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D010523 | Peripheral Nervous System Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Phosphoproteomics will be done in muscle samples using mass spectrometry. All samples will be screened for influence of muscular changes (i.e. Intensive Care Unit Acquired Weakness (ICUAW)) and correlation with blood metabolome changes.
| a median of 14 days |
| a median of 14 days |
| D009468 | Neuromuscular Diseases |
| D009422 | Nervous System Diseases |
| D009140 | Musculoskeletal Diseases |
| D020879 | Neuromuscular Manifestations |
| D009461 | Neurologic Manifestations |
| D012816 | Signs and Symptoms |